These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37971169)

  • 1. CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity.
    Haydar D; Ibañez-Vega J; Crawford JC; Chou CH; Guy CS; Meehl M; Yi Z; Perry S; Laxton J; Cunningham T; Langfitt D; Vogel P; DeRenzo C; Gottschalk S; Roussel MF; Thomas PG; Krenciute G
    Cancer Res Commun; 2023 Dec; 3(12):2430-2446. PubMed ID: 37971169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity.
    Haydar D; Ibañez-Vega J; Crawford JC; Chou CH; Guy C; Meehl M; Yi Z; Langfitt D; Vogel P; DeRenzo C; Gottschalk S; Roussel MF; Thomas PG; Krenciute G
    Res Sq; 2023 Jun; ():. PubMed ID: 37333156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells.
    Nguyen P; Okeke E; Clay M; Haydar D; Justice J; O'Reilly C; Pruett-Miller S; Papizan J; Moore J; Zhou S; Throm R; Krenciute G; Gottschalk S; DeRenzo C
    Mol Ther Oncolytics; 2020 Sep; 18():202-214. PubMed ID: 32728609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.
    Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X
    Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
    Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
    Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
    Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
    Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
    Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
    Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
    Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
    Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
    Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.